• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

营养状况作为晚期头颈癌免疫治疗结果的预测生物标志物

Nutritional Status as a Predictive Biomarker for Immunotherapy Outcomes in Advanced Head and Neck Cancer.

作者信息

Guller Meytal, Herberg Matthew, Amin Neha, Alkhatib Hosam, Maroun Christopher, Wu Evan, Allen Hailey, Zheng Ying, Gourin Christine, Vosler Peter, Tan Marietta, Koch Wayne, Eisele David, Seiwert Tanguy, Fakhry Carole, Pardoll Drew, Zhu Gangcai, Mandal Rajarsi

机构信息

Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University, Baltimore, MD 21287, USA.

Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore, MD 21287, USA.

出版信息

Cancers (Basel). 2021 Nov 18;13(22):5772. doi: 10.3390/cancers13225772.

DOI:10.3390/cancers13225772
PMID:34830929
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8616447/
Abstract

The association between pretreatment nutritional status and immunotherapy response in patients with advanced head and neck cancer is unclear. We retrospectively analyzed a cohort of 99 patients who underwent treatment with anti-PD-1 or anti-CTLA-4 antibodies (or both) for stage IV HNSCC between 2014 and 2020 at the Johns Hopkins Hospital. Patient demographics and clinical characteristics were retrieved from electronic medical records. Baseline prognostic nutritional index (PNI) scores and pretreatment body mass index (BMI) trends were calculated. Associations between PNI and BMI were correlated with overall survival (OS), progression-free survival (PFS), and immunotherapy response. In univariate analysis, there was a significant correlation between OS and PFS with baseline PNI (OS: HR: 0.464; 95% CI: 0.265-0.814; PFS: = 0.007 and HR: 0.525; 95% CI: 0.341-0.808; = 0.003). Poor OS was also associated with a greater decrease in pretreatment BMI trend (HR: 0.42; 95% CI: 0.229-0.77; = 0.005). In multivariate analysis, baseline PNI but not BMI trend was significantly associated with OS and PFS (OS: log (HR) = -0.79, CI: -1.6, -0.03, = 0.041; PFS: log (HR) = -0.78, CI: -1.4, -0.18, = 0.011). In conclusion, poor pretreatment nutritional status is associated with negative post-immunotherapy outcomes.

摘要

晚期头颈癌患者治疗前营养状况与免疫治疗反应之间的关联尚不清楚。我们回顾性分析了2014年至2020年在约翰霍普金斯医院接受抗PD-1或抗CTLA-4抗体(或两者)治疗的99例IV期头颈部鳞状细胞癌(HNSCC)患者队列。从电子病历中获取患者的人口统计学和临床特征。计算基线预后营养指数(PNI)评分和治疗前体重指数(BMI)趋势。PNI和BMI与总生存期(OS)、无进展生存期(PFS)和免疫治疗反应之间的关联。单因素分析中,OS和PFS与基线PNI之间存在显著相关性(OS:HR:0.464;95%CI:0.265 - 0.814;P = 0.007;PFS:HR:0.525;95%CI:0.341 - 0.808;P = 0.003)。较差的OS也与治疗前BMI趋势的更大下降相关(HR:0.42;95%CI:0.229 - 0.77;P = 0.005)。多因素分析中,基线PNI而非BMI趋势与OS和PFS显著相关(OS:log(HR)= -0.79,CI:-1.6,-0.03,P = 0.041;PFS:log(HR)= -0.78,CI:-1.4,-0.18,P = 0.011)。总之,治疗前营养状况较差与免疫治疗后不良结局相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d2a/8616447/449bc137a97d/cancers-13-05772-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d2a/8616447/748cd532256a/cancers-13-05772-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d2a/8616447/0dad08b30773/cancers-13-05772-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d2a/8616447/449bc137a97d/cancers-13-05772-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d2a/8616447/748cd532256a/cancers-13-05772-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d2a/8616447/0dad08b30773/cancers-13-05772-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d2a/8616447/449bc137a97d/cancers-13-05772-g003.jpg

相似文献

1
Nutritional Status as a Predictive Biomarker for Immunotherapy Outcomes in Advanced Head and Neck Cancer.营养状况作为晚期头颈癌免疫治疗结果的预测生物标志物
Cancers (Basel). 2021 Nov 18;13(22):5772. doi: 10.3390/cancers13225772.
2
Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.治疗前预后营养指数作为一种新型生物标志物在接受免疫检查点抑制剂治疗的非小细胞肺癌患者中的应用。
Lung Cancer. 2019 Oct;136:45-51. doi: 10.1016/j.lungcan.2019.08.006. Epub 2019 Aug 14.
3
Prognostic nutritional index predicts the prognosis of patients with advanced esophageal cancer treated with immune checkpoint inhibitors: a retrospective cohort study.预后营养指数可预测接受免疫检查点抑制剂治疗的晚期食管癌患者的预后:一项回顾性队列研究
J Gastrointest Oncol. 2023 Feb 28;14(1):54-63. doi: 10.21037/jgo-23-48. Epub 2023 Feb 24.
4
Predictive value of nutritional indicators with regard to the survival outcomes in patients with metastatic esophageal squamous cell carcinoma treated with camrelizumab.卡瑞利珠单抗治疗转移性食管鳞状细胞癌患者时营养指标对生存结局的预测价值
Oncol Lett. 2023 Apr 3;25(5):198. doi: 10.3892/ol.2023.13784. eCollection 2023 May.
5
The Prognostic Value of the Prognostic Nutritional Index in Patients with Advanced or Metastatic Gastric Cancer Treated with Immunotherapy.预后营养指数对接受免疫治疗的晚期或转移性胃癌患者的预后价值。
Nutrients. 2023 Oct 8;15(19):4290. doi: 10.3390/nu15194290.
6
Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients.营养状况与复发或转移性头颈部鳞状细胞癌患者的免疫治疗临床结局相关。
Oral Oncol. 2023 May;140:106364. doi: 10.1016/j.oraloncology.2023.106364. Epub 2023 Mar 28.
7
Nutritional status as prognostic factor of advanced oesophageal cancer patients treated with immune checkpoint inhibitors.营养状况作为免疫检查点抑制剂治疗晚期食管癌患者的预后因素。
Clin Nutr. 2024 Jan;43(1):142-153. doi: 10.1016/j.clnu.2023.11.030. Epub 2023 Nov 27.
8
Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.术前预后营养指数作为转移性肾细胞癌患者一线靶向治疗酪氨酸激酶抑制剂预后预测指标的意义
Int Urol Nephrol. 2017 Nov;49(11):1955-1963. doi: 10.1007/s11255-017-1693-9. Epub 2017 Sep 9.
9
The association between body mass index and efficacy of pembrolizumab as second-line therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma.体重指数与帕博利珠单抗二线治疗复发性/转移性头颈部鳞状细胞癌疗效的相关性。
Cancer Med. 2023 Feb;12(3):2702-2712. doi: 10.1002/cam4.5152. Epub 2022 Aug 17.
10
Prognostic Role of Pretreatment Prognostic Nutritional Index in Advanced Lung Cancer Patients Receiving First-Line Immunotherapy: A Meta-Analysis.治疗前预后营养指数在接受一线免疫治疗的晚期肺癌患者中的预后作用:一项荟萃分析
Cureus. 2024 Jan 22;16(1):e52720. doi: 10.7759/cureus.52720. eCollection 2024 Jan.

引用本文的文献

1
Prognostic significance of prognostic nutritional index in patients with head and neck squamous cell carcinoma.预后营养指数在头颈部鳞状细胞癌患者中的预后意义
Front Immunol. 2025 Aug 27;16:1597965. doi: 10.3389/fimmu.2025.1597965. eCollection 2025.
2
Nutritional status, immunonutrition, and gut microbiome: a coming of age for immunotherapy?营养状况、免疫营养与肠道微生物群:免疫疗法走向成熟?
Front Immunol. 2025 Aug 25;16:1612567. doi: 10.3389/fimmu.2025.1612567. eCollection 2025.
3
The role of prognostic nutrition index in the prognosis of patients with advanced hepatocellular carcinoma who received first-line therapy.

本文引用的文献

1
Prognostic Nutritional Index Predicts Toxicity in Head and Neck Cancer Patients Treated with Definitive Radiotherapy in Association with Chemotherapy.预后营养指数预测联合化疗行根治性放疗的头颈部癌症患者的毒性。
Nutrients. 2021 Apr 13;13(4):1277. doi: 10.3390/nu13041277.
2
Impact of BMI on Survival Outcomes of Immunotherapy in Solid Tumors: A Systematic Review.BMI 对实体瘤免疫治疗生存结局的影响:系统评价。
Int J Mol Sci. 2021 Mar 5;22(5):2628. doi: 10.3390/ijms22052628.
3
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.
预后营养指数在接受一线治疗的晚期肝细胞癌患者预后中的作用。
BMC Cancer. 2025 Aug 2;25(1):1258. doi: 10.1186/s12885-025-14672-1.
4
Nutritional conditions and PFS and OS in cancer immunotherapy: the MOUSEION-010 meta-analysis.癌症免疫治疗中的营养状况与无进展生存期和总生存期:MOUSEION - 010荟萃分析
Immunotherapy. 2025 Mar;17(4):269-281. doi: 10.1080/1750743X.2025.2483656. Epub 2025 Mar 25.
5
Efficacy Assessment and Prognostic Value of Inflammatory Markers in Patients with Stage IV Acral and Cutaneous Melanoma Receiving PD-1 Inhibitors.接受PD-1抑制剂治疗的IV期肢端和皮肤黑色素瘤患者炎症标志物的疗效评估及预后价值
J Inflamm Res. 2025 Feb 20;18:2531-2544. doi: 10.2147/JIR.S509928. eCollection 2025.
6
Inverse association between prognostic nutritional index and kidney stone prevalence: A population-based study.预后营养指数与肾结石患病率之间的负相关关系:一项基于人群的研究。
PLoS One. 2025 Feb 18;20(2):e0318254. doi: 10.1371/journal.pone.0318254. eCollection 2025.
7
BMI Association With Treatment Outcomes in Head and Neck Cancer Patients Receiving Immunotherapy: A Comprehensive Review and Meta-Analysis.体重指数与接受免疫治疗的头颈癌患者治疗结果的关联:一项全面综述与荟萃分析
Cancer Rep (Hoboken). 2025 Feb;8(2):e70147. doi: 10.1002/cnr2.70147.
8
Prognostic value of inflammatory and nutritional indexes among patients with unresectable advanced gastric cancer receiving immune checkpoint inhibitors combined with chemotherapy-a retrospective study.不可切除的晚期胃癌患者接受免疫检查点抑制剂联合化疗时炎症和营养指标的预后价值——一项回顾性研究
PeerJ. 2024 Dec 17;12:e18659. doi: 10.7717/peerj.18659. eCollection 2024.
9
Combined systemic immune-inflammatory index and prognostic nutritional index predicts the efficacy and prognosis of ES-SCLC patients receiving PD-L1 inhibitors combined with first-line chemotherapy.联合全身免疫炎症指数和预后营养指数可预测广泛期小细胞肺癌患者接受程序性死亡受体配体1抑制剂联合一线化疗的疗效和预后。
Front Oncol. 2024 Dec 4;14:1485849. doi: 10.3389/fonc.2024.1485849. eCollection 2024.
10
Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzle.肠道微生物群与癌症免疫治疗反应的营养相关预测因素:解开谜团
BJC Rep. 2023 Aug 2;1(1):5. doi: 10.1038/s44276-023-00008-8.
高肿瘤突变负担未能预测所有癌症类型的免疫检查点阻断反应。
Ann Oncol. 2021 May;32(5):661-672. doi: 10.1016/j.annonc.2021.02.006. Epub 2021 Mar 15.
4
Clinical significance of pretreatment prognostic nutritional index and lymphocyte-to-monocyte ratio in patients with advanced p16-negative oropharyngeal cancer-a retrospective study.晚期p16阴性口咽癌患者治疗前预后营养指数和淋巴细胞与单核细胞比值的临床意义——一项回顾性研究
PeerJ. 2020 Dec 1;8:e10465. doi: 10.7717/peerj.10465. eCollection 2020.
5
Baseline prognostic nutritional index and changes in pretreatment body mass index associate with immunotherapy response in patients with advanced cancer.基线预后营养指数和治疗前体重指数变化与晚期癌症患者的免疫治疗反应相关。
J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-001674.
6
Body mass index (BMI) and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy: a multicenter international retrospective study.体重指数(BMI)与接受靶向治疗和免疫治疗的转移性黑色素瘤患者的结局:一项多中心国际回顾性研究。
J Immunother Cancer. 2020 Nov;8(2). doi: 10.1136/jitc-2020-001117.
7
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation.一线帕博利珠单抗治疗 PD-L1 表达≥50%的 NSCLC 患者的基线 BMI 及治疗期间 BMI 变化:一项多中心研究及外部验证。
J Immunother Cancer. 2020 Oct;8(2). doi: 10.1136/jitc-2020-001403.
8
Impact of body composition on outcomes from anti-PD1 +/- anti-CTLA-4 treatment in melanoma.抗 PD-1/抗 CTLA-4 治疗对黑色素瘤患者结局的影响:与人体成分的关系。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000821.
9
A Literature Review of the Potential Diagnostic Biomarkers of Head and Neck Neoplasms.头颈部肿瘤潜在诊断生物标志物的文献综述
Front Oncol. 2020 Jun 26;10:1020. doi: 10.3389/fonc.2020.01020. eCollection 2020.
10
Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors.PD-1 抑制剂治疗晚期非小细胞肺癌的外周血标志物预测疗效和免疫相关不良事件。
Cancer Immunol Immunother. 2020 Sep;69(9):1813-1822. doi: 10.1007/s00262-020-02585-w. Epub 2020 Apr 29.